Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of MIL62 in primary membranous nephropathy
CTR20212715Phase 2Completed
- Sponsor
- Mabworks Biotech
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Bejescin in idiopathic membranous glomerulonephritis (IMG), sponsored by Mabworks Biotech. Started Feb 2022; status: completed.
02
Drugs
Bejescin
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20212715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212715.